Trevena, Inc. (TRVN)
Sector: Biotechnology
Industry: Biotechnology
Trevena, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 977 |
| Nov 10, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 117 |
| Oct 26, 2026 | 0.0111 | 0.0111 | 0.0111 | 0.0111 | 254 |
| Oct 16, 2026 | 0.0004 | 0.0005 | 0.0004 | 0.0005 | 4,129 |
| Oct 12, 2026 | 0.0660 | 0.0660 | 0.0660 | 0.0660 | 833 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Acting CEO | Automatic Sell | 1.1K | $1.6K | Oct 8, 2024 | |
| Acting CEO | Automatic Sell | 285 | $418.95 | Oct 8, 2024 | |
| Acting CEO | Automatic Sell | 285 | $418.95 | Oct 8, 2024 | |
| Acting CMO | Automatic Sell | 20 | $29.4 | Oct 8, 2024 | |
| Acting CMO | Automatic Sell | 45 | $66.15 | Oct 8, 2024 | |
| Acting CMO | Automatic Sell | 144 | $211.68 | Oct 8, 2024 |
| Name | Shares | % | Source |
|---|---|---|---|
Armistice Capital, LLC · joint filing· may incl. warrants· filed Nov 2026 | 95.0K | 11.0% | 13G |
Bourdow Carrie L. Acting CEO, Director | 23.9K | 2.8% | FORM 4 |
Shin Barry Acting COO and CFO | 11.5K | 1.3% | FORM 4 |
Demitrack Mark Acting CMO | 11.4K | 1.3% | FORM 4 |
Yoder Robert T SVP, Chief Business Officer | 5.9K | 0.7% | FORM 4 |
Sutton Katrine VP, Finance | 942 | 0.1% | FORM 4 |
Planning Capital Management Corp | 3 | 0.0% | 13F |
Insiders
- Bourdow Carrie L.Acting CEO
- Demitrack MarkActing CMO
- Shin BarryActing COO and CFO
- Yoder Robert TSVP, Chief Business Officer
- Sutton KatrineVP, Finance
Top institutional holders
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders.
Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
based on 863,788 shares outstanding
30d Avg
449
60d Avg
707
90d Avg
778
Trevena, Inc. (OTC: TRVN) traded at $0.0005 on Nov 13, 2026. 52-week range: $0.0003 to $0.0400. The company is in the Healthcare sector (Biotechnology).